* Aerie pharmaceuticals completes enrollment of mercury 2
phase 3 registration trial of roclatan(tm)
(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
The post BRIEF-Aerie Pharma completes enrollment of mercury 2 phase 3 registration trial of roclatan appeared first on NASDAQ.